Stay updated on Enfortumab Vedotin Combo vs. Chemo Alone in Urothelial Cancer Clinical Trial
Sign up to get notified when there's something new on the Enfortumab Vedotin Combo vs. Chemo Alone in Urothelial Cancer Clinical Trial page.

Latest updates to the Enfortumab Vedotin Combo vs. Chemo Alone in Urothelial Cancer Clinical Trial page
- CheckyesterdayChange DetectedUpdated the page revision/version indicator from **v3.5.0** to **v3.5.2**.SummaryDifference0.0%

- Check8 days agoNo Change Detected
- Check15 days agoChange DetectedAdded a new publication citation to the Publications section: How enfortumab vedotin plus pembrolizumab affects the quality of life of people with advanced urothelial cancer: Future Oncol (2026).SummaryDifference0.0%

- Check23 days agoChange DetectedAdded a 2026 Pan-Asian subgroup analysis paper on EV-302 and removed the online-ahead-of-print version of the same article from the Publications list.SummaryDifference0.0%

- Check30 days agoChange DetectedRevision indicator updated: added Revision v3.5.0 and removed Revision v3.4.3.SummaryDifference0.0%

- Check44 days agoChange DetectedRevision updated from v3.4.2 to v3.4.3.SummaryDifference0.0%

- Check66 days agoChange DetectedRevision updated to v3.4.2 from v3.4.1. This is a minor UI/system update with no impact on study content, eligibility, or results; To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.0%

Stay in the know with updates to Enfortumab Vedotin Combo vs. Chemo Alone in Urothelial Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Enfortumab Vedotin Combo vs. Chemo Alone in Urothelial Cancer Clinical Trial page.